| Tuberculosis and lung damage: from epidemiology to pathophysiology |
40 |
| Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases |
37 |
| Exacerbations of COPD |
36 |
| Indoor mould exposure, asthma and rhinitis: findings from systematic reviews and recent longitudinal studies |
25 |
| Neutrophil to lymphocyte ratio and clinical outcomes in COPD: recent evidence and future perspectives |
24 |
| Acute exacerbations of progressive-fibrosing interstitial lung diseases |
24 |
| Physiology of the lung in idiopathic pulmonary fibrosis |
24 |
| Fibrosing interstitial lung diseases: knowns and unknowns |
23 |
| Immunological and toxicological risk assessment of e-cigarettes |
22 |
| Cardiovascular disease and COPD: dangerous liaisons? |
22 |
| Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence |
21 |
| The therapy of idiopathic pulmonary fibrosis: what is next? |
19 |
| Matrix abnormalities in pulmonary fibrosis |
17 |
| Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis |
17 |
| The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype |
17 |
| Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives |
17 |
| Cadmium in tobacco smokers: a neglected link to lung disease? |
16 |
| Respiratory viral infection: a potential missing link in the pathogenesis of COPD |
16 |
| Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer |
16 |
| Obesity hypoventilation syndrome |
15 |
| ERS statement on standardisation of cardiopulmonary exercise testing in chronic lung diseases |
14 |
| Management of pulmonary toxicity associated with immune checkpoint inhibitors |
14 |
| Cancer-associated thrombosis: the when, how and why |
13 |
| Adipose tissue as a key player in obstructive sleep apnoea |
13 |
| Personalised pulmonary rehabilitation in COPD |
12 |
| State of the art in interstitial pneumonia with autoimmune features: a systematic review on retrospective studies and suggestions for further advances |
12 |
| Tuberculosis elimination where are we now? |
12 |
| How long is too long? A scoping review of health system delays in lung cancer |
11 |
| Precision medicine in COPD: where are we and where do we need to go? |
11 |
| The use of chest magnetic resonance imaging in interstitial lung disease: a systematic review |
11 |
| Cellular mechanisms underlying steroid-resistant asthma |
11 |
| The role of cardiopulmonary exercise tests in pulmonary arterial hypertension |
10 |
| Acellular human lung scaffolds to mode lung disease and tissue regeneration |
10 |
| Noninvasive ventilation in acute respiratory failure: which recipe for success? |
10 |
| The broad spectrum of lung diseases in primary antibody deficiencies |
10 |
| Particulate matter and the airway epithelium: the special case of the underground? |
9 |
| Role of imaging in progressive-fibrosing interstitial lung diseases |
9 |
| Severe T2-high asthma in the biologics era: European experts' opinion |
8 |
| Influence of the lung microbiome on antibiotic susceptibility of cystic fibrosis pathogens |
8 |
| Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease |
8 |
| Telemedicine in the diagnosis and treatment of sleep apnoea |
8 |
| Women and COPD: do we need more evidence? |
8 |
| COPD stands for complex obstructive pulmonary disease |
8 |
| Sarcopenia in COPD: a systematic review and meta-analysis |
8 |
| Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue |
8 |
| Bronchiectasis: a case-based approach to investigation and management |
8 |
| Patients' perceptions and patient reported outcomes in progressive-fibrosing interstitial lung diseases |
7 |
| The contribution of infection and the respiratory microbiome in acute exacerbations of idiopathic pulmonary fibrosis |
7 |
| Endobronchial valves for severe emphysema |
7 |
| Breath analysis of cancer in the present and the future |
7 |
